Vaginal Progesterone Did Not Improve Live Birth Rates in Women with Recurrent Miscarriage

Nonetheless, the chances of subsequent live birth remain as high as 70%.

Despite intensive research in recurrent miscarriage, most cases remain unexplained and no treatment modality has proved effective. In a multicenter trial in Great Britain and the Netherlands, researchers examined whether treatment with vaginal progesterone would improve live birth rates among women with unexplained recurrent miscarriage (defined in this study as loss of 3 or more pregnancies). A total of 836 participants were randomized to receive vaginal progesterone suppositories (400 mg twice daily) or placebo beginning no later than 6 weeks' gestation and extending through 12 weeks' gestation.

In intention-to-treat analysis, the rate of live birth after 24 weeks' gestation was 66% in the progesterone arm and 63% in the placebo arm (relat…

Reviewing Author

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Vaginal Progesterone Did Not Improve Live Birth Rates in Women with Recurrent Miscarriage

Topics

Reviewing Author